DBV Technologies ADR (DBVT)

Currency in USD
10.550
-0.660(-5.89%)
Closed·
10.420-0.130(-1.23%)
·
Advertisement
Trading near 52-week Low
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.47011.010
52 wk Range
10.47026.185
Key Statistics
Prev. Close
10.55
Open
10.92
Day's Range
10.47-11.01
52 wk Range
10.47-26.185
Volume
673.3K
Average Volume (3m)
321.29K
1-Year Change
-18.2171%
Book Value / Share
0.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.774
Upside
+267.53%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

DBV Technologies ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 38.774
(+267.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy55.00+421.33%-Maintain30/09/2026
Cantor Fitzgerald
Buy48.00+354.98%48.00Maintain10/09/2026
Cantor Fitzgerald
Buy48.00+354.98%48.00Maintain17/07/2026
Citizens
Buy55.00+421.33%-Maintain17/07/2026
Citizens
Buy55.00+421.33%47.00Maintain01/05/2026

DBV Technologies ADR SWOT Analysis


Allergy Innovation
Explore DBV Technologies' groundbreaking Viaskin Peanut patch, offering a non-invasive solution for peanut allergies in children with promising clinical results
Market Potential
Delve into the projected $2 billion annual peak sales for Viaskin Peanut, driven by strong physician intent and a growing patient base
Financial Outlook
Learn about DBV's improved financial position, with $128 million in cash and potential for $180 million more, despite current cash burn concerns
Analyst Perspectives
Discover varied analyst price targets ranging from $10 to $21, reflecting optimism about DBV's future prospects in the allergy treatment market
Read full SWOT analysis

DBV Technologies ADR Earnings Call Summary for Q2/2026

  • DBV Technologies remains on track to file its Viaskin Peanut patch BLA with FDA in Q3 2026, requesting priority review; stock fell 5.4% despite progress.
  • Company funded through Q3 2027 but burns $151.5M annually; market cap stands at $949.6M with InvestingPro rating financial health as 'weak.'
  • FDA has not requested additional data for filing; management completing final CMC discussions and biostatistics formatting before submission.
  • Supplemental BLA for toddlers (ages 1-3) planned by end-2026; Phase II THRIVE study launched in infants (6-12 months) to expand market reach.
  • Commercial infrastructure buildout underway including market access, field force planning, and manufacturing capacity review ahead of potential 2027 launch.
Last Updated: 16/07/2026, 23:06
Read Full Transcript

Earnings

Latest Release
16/07/2026
EPS / Forecast
-0.12 / --
Revenue / Forecast
700K / --
EPS Revisions
Last 90 days

Compare DBVT to Peers and Sector

Metrics to compare
DBVT
Peers
Sector
Relationship
P/E Ratio
−3.6x13.6x−0.3x
PEG Ratio
−0.080.160.00
Price/Book
3.9x2.4x2.6x
Price / LTM Sales
125.7x4.0x3.0x
Upside (Analyst Target)
267.6%61.3%58.6%
Fair Value Upside
Unlock15.1%8.4%Unlock

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
170

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.63M3.59%112.18M
Other Institutional Investors
408.22M96.41%4.31B
Public Companies & Retail Investors
0.000.00%0.00
Total
418.85M100.00%4.42B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Healthcare Fund, L.P.12.36%36,576,440385,881
RA Capital Management, L.P.12.36%36,576,440385,881

People Also Watch

4.580
IRD
+1.55%
10.79
MGTX
+1.22%
107.39
KYMR
-2.48%
23.200
NAMS
-3.97%
0.310
CNTX
-1.59%

FAQ

What Is the DBV Technologies ADR (NASDAQ: DBVT) Share Price Today?

The DBV Technologies ADR stock price today is 10.550 USD.

What Stock Exchange Does DBV Technologies ADR (DBVT) Trade On?

DBV Technologies ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for DBV Technologies ADR?

The stock symbol (also called a 'ticker') for DBV Technologies ADR is "DBVT."

What Is the Current DBV Technologies ADR Market Capitalisation?

As of today, DBV Technologies ADR (NASDAQ: DBVT) market cap is 633.960M USD.

What Is DBV Technologies ADR's (DBVT) Earnings Per Share (TTM)?

The DBV Technologies ADR EPS is currently -0.601 (Trailing Twelve Months).

Is DBVT a Buy or Sell From a Technical Analyst Perspective?

Based on today's DBV Technologies ADR moving averages and other technical indicators, the daily buy/sell signal for DBVT stock is Strong Sell.

How Many Times Has DBV Technologies ADR Stock Split?

DBV Technologies ADR has split 2 times. (See the DBVT stock split history page for full effective split date and price information.)

How Many Employees Does DBV Technologies ADR Have?

DBV Technologies ADR has 170 employees, based on their latest Companies House report.

What is the current trading status of DBV Technologies ADR (NASDAQ: DBVT)?

As of 03/10/2026, DBV Technologies ADR (DBVT) is trading at a share price of 10.550 USD, with a previous close of 10.550 USD. The stock has fluctuated within a day range of 10.470 USD to 11.010 USD, while its 52-week range spans from 10.470 USD to 26.185 USD.

What Is DBV Technologies ADR (DBVT) Price Target According to Analysts?

The average 12-month price target for DBV Technologies ADR is 38.774 USD, with a high estimate of 54.61685608 USD and a low estimate of 5.72071565 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +267.53% Upside potential.

What Is the DBVT Premarket Price?

DBVT's last pre-market stock price is 10.840 USD. The pre-market share volume is 16,530.000, and the stock has decreased by -0.370, or -3.300%.

What Is the DBVT After Hours Price?

DBVT's last after hours stock price is 10.420 USD, the stock has decreased by -0.130, or -1.230%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.